Proportion of IgE-mediated allergic reactions to the 2009-2010 pH1N1 vaccine

Proportion of IgE-mediated allergic reactions to the 2009-2010 pH1N1 vaccine Isabelle Rouleau, PhD(c) Faculté de médecine, Université Laval

Research Team ,[object Object],[object Object]

Allergy to pH1N1 vaccine ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Important distiction ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Allergy diagnostic testing ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Study design and participants ,[object Object],[object Object],[object Object],[object Object],[object Object]

Participating Centres ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Testing conditions ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Study outcomes ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Results ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Surveillance reports vs. allergists N=91 22 (24.2) 59 (64.8) 7 (7.7) TOTAL 42 (46.2) 13 (59.1) 26 (44.1) 2 (4.8) Other 10 (11.0) 7 (70.0) 2 (3.4) 1 (14.3) ORS 14 (15.4) 0 (0.0) 13 (22.0) 0 (0.0) Allergy 22 (24.2) 2 (9.1) 15 (25.4) 4 (57.1) Anaphylaxis TOTAL N (col. %) ORS N (col. %) Allergy N (col. %) Anaphylaxis N (col. %) Reports   Allergists

Proportion of positive skin tests 2 (5.6) 14 (15.4) 2 (5.6) 17 (18.7) To any vaccine component 1 (2.9) 7 (9.7) 2 (5.7) 7 (9.7) Reconstituted vaccine (day old) 2 (5.6) 9 (9.9) 2 (5.6) 10 (11.0) Reconstituted vaccine (same day) 1 (2.8) 6 (6.6) 1 (2.8) 11 (12.1) AS03 adjuvant 0 (0.0) 4 (4.4) 1 (2.8) 6 (6.6) pH1N1 antigen N (%) N (%) N (%) N (%) Controls Cases Controls Cases N (%) Positive (ID 5 mm) N (%) Positive (ID 3 mm)

Proportion of positive to prick tests among positives None 0/7 1 (2.9) 7 (9.7) Reconstituted vaccine (day old) None 2/9 (22%) 2 (5.6) 9 (9.9) Reconstituted vaccine (same day) None 2/6 (33%) 1 (2.8) 6 (6.6) AS03 adjuvant None 3/4 (75%) None 4 (4.4) pH1N1 antigen N (%) N (%) N (%) N (%) Controls Cases Controls Cases Positive to Prick test N (%) Positive (ID 5 mm)

Positive skin tests (prick or ID of 5 mm) by type of case 7(15.6) 1 (10.0) 1 (7.1) 5 (22.7) 2 (5.6) To any vaccine component 3 (7.7) 1 (12.5) 0 (0.0) 3 (15.8) 2 (5.7) Reconstituted vaccine (day old) 6 (13.3) 0 (0.0) 0 (0.0) 3 (13.6) 2 (5.6) Reconstituted vaccine (same day) 2 (4.4) 1 (10.0) 1 (7.1) 2 (9.1) 1 (2.8) AS03 adjuvant 2 (4.4) 0 (0.0) 1 (7.1) 1 (4.6) 0 (0.0) pH1N1 antigen N (%) N (%) N (%) N (%) N (%) Other ORS Allergy Anaphyl. Controls

Positive skin tests (ID 5mm), by component and type of reaction

Positives to reconstituted vaccine ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Revaccination of positive cases ,[object Object],[object Object],[object Object],[object Object]

Revaccination of negative cases ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Conclusions ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Conclusions ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

PHAC-sponsored components ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Proportion of IgE-mediated allergic reactions to the 2009-2010 pH1N1 vaccine

Recommended

Recommended

More Related Content

What's hot

What's hot (9)

Viewers also liked

Viewers also liked (17)

Similar to Proportion of IgE-mediated allergic reactions to the 2009-2010 pH1N1 vaccine

Similar to Proportion of IgE-mediated allergic reactions to the 2009-2010 pH1N1 vaccine (20)

Recently uploaded

Recently uploaded (20)

Proportion of IgE-mediated allergic reactions to the 2009-2010 pH1N1 vaccine